DRD2 and psychiatric disorder: Although measuring autoantibodies and understanding their impact is always a challenge in human disease, a subgroup of patients with both movement and psychiatric disorders (basal ganglia autoimmunity) suggest that antibodies against cell surface D2 dopamine receptors (D2R) [128] may be involved.